Pristimerin Protects Against Doxorubicin-Induced Cardiomyopathy and Fibrosis | ||||
Cardiovascular Research Prove Journal | ||||
Volume 3, Issue 1, June 2019 PDF (34.72 K) | ||||
Document Type: Abstracts | ||||
DOI: 10.21608/cvrepj.2019.351824 | ||||
View on SCiNiTO | ||||
Abstract | ||||
Pristimerin (Pris) is triterpenoid compound with many biological effects. Until now, nothing is known about its effect on doxorubicin (DOX)-induced cardiotoxicity. Hence, this study investigated the impact of Pris on DOX-induced cardiotoxic effects. | ||||
Statistics Article View: 13 PDF Download: 8 |
||||